Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 10, 2010, Pages 3146-3149

  Jerome, Kevin D ^a   Hepperle, Michael E ^a   Walker, John K ^a   Xing, Li ^a   Devraj, Rajesh V ^a   Benson, Alan G ^a   Baldus, John E ^a   Selness, Shaun R ^a  

^a PFIZER INC   (United States)

Author keywords

Kinase; p38; Pyridazinones

Indexed keywords

2,4 DIFLUOROBENZYLOXY; 4,5 DIBROMO PYRIDAZINONE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 SUBSTITUTED N ARYLPYRIDAZINONE DERIVATIVE; 6 ARYLAMINO 2 ARYLPYRIDAZIN 3ONE; 6 IMIDAZOPYRIDYL 2 ARYLPYRIDAZIN 3 ONE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N 2 SUBSTITUTED 4,5 DIBROMO PYRIDAZINONE; PYRIDAZINONE DERIVATIVE; PYRIDONE DERIVATIVE; SC 25028; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME MECHANISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ANTI-INFECTIVE AGENTS; BINDING SITES; COMPUTER SIMULATION; DRUG DISCOVERY; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE INHIBITORS; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952103803     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.088     Document Type: Article

References (25)

1. Dominguez C., Tamayo N., and Zhang D. Expert Opin. Ther. Pat. 15 (2005) 801
2. Arend W.P., and Dayer J.M. Arthritis Rheum. 33 (1990) 305
3. Firestein G.S., Alvaro-Gracia J.M., and Maki R. J. Immunol. 144 (1990) 3347
4. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., Shaible T.F., and Van Deventer S.J.H. Gastroenterology 117 (1999) 761
5. Ulfgren A.K., Andersson U., Engstrom M., Klareskog L., Maini R.N., and Taylor P.C. Arthritis Rheum. 43 (2000) 2391
6. Foster M.L., Halley F., and Souness J.E. Drug News Perspect. 13 (2000) 488
7. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., MeNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., and Young P.R. Nature 372 (1994) 739
8. Enbrel is a marketed soluble TNF-α receptor and Remicade is marketed as a TNF-α antibody therapy:. Jarvis B., and Faulds D. Drugs 57 (1999) 945
9. Rutgeerts P.J. Aliment. Pharmacol. Ther. 13 (1999) 9
10. Seymour H.E., Worsley A., Smith J.M., and Thomas S.H.L. Br. J. Clin. Pharmacol. 51 (2001) 201
11. For other clinical examples of p-38 map kinase inhibitors efficacy see:. Ferraccioli G.F. Curr. Opin. Anti-Inflamm. Immunomodulat. Invest. Drugs 2 (2000) 74
12. Bemis, G. W.; Salituro, F. G.; Duffy, J. P.; Cochran, J. E.; Harrington, E. M.; Murcko,. M. A.; Wilson, K. P.; Su, M.; Galullo, V. P. U.S. Patent 7,365,072 B2, 2008.
13. Bemis, G. W.; Salituro, F. G.; Duffy, J .P.; Harrington, E. M. U.S. Patent 6,147,080, 2000.
14. Colletti S.L., Frie J.L., Dixon E.C., Singh S.B., Choi B.K., Scapin G., Fitzgerald C.E., Kumar S., Nichols E.A., O'Keefe S.J., O'Neill E.A., Porter G., Samuel K., Schmatz D.M., Schwartz C.D., Shoop W.L., Thompson C.M., Thompson J.E., Wang R., Woods A., Zaller D.M., and Doherty J.B. J. Med. Chem. 46 (2003) 349
15. Natarajan S.R., Heller S.T., Nam K., Singh S.B., Scapin G., Patel S., Thompson J.E., Fitzgerald C.E., and O'Keefe S.J. Bioorg. Med. Chem. Lett. 16 (2006) 5809
16. Selness S.R., Devraj R.V., Monahan J.B., Boehm T.L., Walker J.K., Devadas B., Durley R.C., Kurumbail R., Shieh H., Xing L., Hepperle M., Jerome K.D., Benson A.G., Marrufo L.D., Madsen H.M., Hitchcock J., Owen T.J., Christie L., Promo M.A., Hickory B.S., Alvira E., Naing W., and Blevis-Bal R. Bioorg. Med. Chem. Lett. 19 (2009) 5851
17. Xing L., Shieh H.S., Selness S.R., Devraj R.V., Walker J.K., Devadas B., Hope H.R., Compton R.P., Schindler J.F., Hirsch J.L., Benson A.G., Kurumbail R.G., Stegeman R.A., Williams J.M., Broadus R.M., Walden Z., and Monahan J.B. Biochemistry 48 (2009) 6402
18. Full disclosure of chemistry methods is made in the following patent application: Devraj, R., Hepperle, M.; Jerome, K.; Selness, S.; Walker, J. K. PCT Int. Appl. 2005, 169 pp. WO 2005007632.
19. Santagati N.A., Duro F., Caruso A., Trombadore S., and Amico-Roxas M. Farmaco, Ediz. Sci. 40 (1985) 921
20. Gudriniece E., and Karklins A. Latv. PSR Zinat. Akad. Vestis Kim. Ser. 4 (1967) 474
21. Bourdais S. Bull. Soc. Chim. Fr. (1964) 2124
22. Matyus P., Czako K., Behr A., Varga I., Podanyi B., Von Arnim M., and Varkonyi P. Heterocycles 36 (1993) 785
23. Gomez-Gil M.C., Gomez-Parra V., Sanchez F., and Torres T. Liebigs Ann. Chem. (1985) 1465
24. Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Arthurs S., Colson A.B., Freer S.T., Larson V., Luty B.A., Marrone T., and Rose P.W. J. Comput. Aided Mol. Des. 14 (2000) 731
25. DFT calculation is performed at B3LYP/6-31G** level, with full geometry optimization in Jaguar 7.6, Schrodinger, LLC, New York, NY.